PHEBRA has signed an exclusive
distribution agreement with
Protherics Medicines Development
to distribute DigiFab (digoxin
immune fab (ovine) ), an antidote
for the treatment of patients
suffering life-threatening digoxin
toxicity, in Australia and NZ.
DigiFab has not yet received
Australian or NZ marketing approval,
however Phebra’s CEO, Dr Mal Eutick
has said that this is something that
the company intends to pursue.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 12
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.